These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 20448478)

  • 1. Novel therapeutic targets for axonal degeneration in multiple sclerosis.
    Petratos S; Azari MF; Ozturk E; Papadopoulos R; Bernard CC
    J Neuropathol Exp Neurol; 2010 Apr; 69(4):323-34. PubMed ID: 20448478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neuronal injury in multiple sclerosis].
    Correale J; Meli F; Ysrraelit C
    Medicina (B Aires); 2006; 66(5):472-85. PubMed ID: 17137182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axon loss is responsible for chronic neurological deficit following inflammatory demyelination in the rat.
    Papadopoulos D; Pham-Dinh D; Reynolds R
    Exp Neurol; 2006 Feb; 197(2):373-85. PubMed ID: 16337942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models.
    Lassmann H
    Exp Neurol; 2010 Sep; 225(1):2-8. PubMed ID: 19840788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axonal degeneration in multiple sclerosis: defining therapeutic targets by identifying the causes of pathology.
    Lee JY; Biemond M; Petratos S
    Neurodegener Dis Manag; 2015 Dec; 5(6):527-48. PubMed ID: 26619755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Astrocyte-associated axonal damage in pre-onset stages of experimental autoimmune encephalomyelitis.
    Wang D; Ayers MM; Catmull DV; Hazelwood LJ; Bernard CC; Orian JM
    Glia; 2005 Aug; 51(3):235-40. PubMed ID: 15812814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation.
    Petratos S; Ozturk E; Azari MF; Kenny R; Lee JY; Magee KA; Harvey AR; McDonald C; Taghian K; Moussa L; Mun Aui P; Siatskas C; Litwak S; Fehlings MG; Strittmatter SM; Bernard CC
    Brain; 2012 Jun; 135(Pt 6):1794-818. PubMed ID: 22544872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of acute axonal damage, Wallerian degeneration, and clinical disability in multiple sclerosis.
    Singh S; Dallenga T; Winkler A; Roemer S; Maruschak B; Siebert H; Brück W; Stadelmann C
    J Neuroinflammation; 2017 Mar; 14(1):57. PubMed ID: 28302146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurodegeneration in autoimmune CNS inflammation.
    Herz J; Zipp F; Siffrin V
    Exp Neurol; 2010 Sep; 225(1):9-17. PubMed ID: 19961850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis.
    Herrero-Herranz E; Pardo LA; Gold R; Linker RA
    Neurobiol Dis; 2008 May; 30(2):162-73. PubMed ID: 18342527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophages and neurodegeneration.
    Hendriks JJ; Teunissen CE; de Vries HE; Dijkstra CD
    Brain Res Brain Res Rev; 2005 Apr; 48(2):185-95. PubMed ID: 15850657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease.
    Bjartmar C; Wujek JR; Trapp BD
    J Neurol Sci; 2003 Feb; 206(2):165-71. PubMed ID: 12559505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurodegeneration in autoimmune demyelination: recent mechanistic insights reveal novel therapeutic targets.
    Aktas O; Waiczies S; Zipp F
    J Neuroimmunol; 2007 Mar; 184(1-2):17-26. PubMed ID: 17222462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate.
    Aharoni R; Vainshtein A; Stock A; Eilam R; From R; Shinder V; Arnon R
    J Autoimmun; 2011 Nov; 37(3):228-41. PubMed ID: 21752599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis.
    Gresle MM; Shaw G; Jarrott B; Alexandrou EN; Friedhuber A; Kilpatrick TJ; Butzkueven H
    J Neurosci Res; 2008 Dec; 86(16):3548-55. PubMed ID: 18709652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of axonal degeneration in EAE--lessons from CNTF and MHC I knockout mice.
    Linker RA; Sendtner M; Gold R
    J Neurol Sci; 2005 Jun; 233(1-2):167-72. PubMed ID: 15949503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axonal degeneration is an early pathological feature in autoimmune-mediated demyelination in mice.
    Onuki M; Ayers MM; Bernard CC; Orian JM
    Microsc Res Tech; 2001 Mar; 52(6):731-9. PubMed ID: 11276125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS.
    Craner MJ; Damarjian TG; Liu S; Hains BC; Lo AC; Black JA; Newcombe J; Cuzner ML; Waxman SG
    Glia; 2005 Jan; 49(2):220-9. PubMed ID: 15390090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Axonal damage and its significance for the concept of neurodegeneration in multiple sclerosis].
    Recks MS; Bader J; Kaiser CC; Schroeter M; Fink GR; Addicks K; Kuerten S
    Fortschr Neurol Psychiatr; 2011 Mar; 79(3):161-70. PubMed ID: 21394707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuronal NF-κB ablation does not influence neuro-axonal degeneration in experimental autoimmune demyelination.
    Lee DH; Kubera K; Rosenthal B; Kaltschmidt B; Kaltschmidt C; Gold R; Linker RA
    J Neuroimmunol; 2012 May; 246(1-2):38-42. PubMed ID: 22475633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.